Purchase Order 75N95023P00326
Award Date
6/5/23
Potential Completion Date
6/4/25
Potential Value
$136K
Funding Federal Agency
National Center for Advancing Translational Sciences
Contracting Federal Agency
National Institute on Drug Abuse
Awardee
Southern Research Institute
Ultimate Awardee
Not listed
NAICS Category
541380 - Testing Laboratories and Services
PSC Category
Q301 - Reference Laboratory Testing
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Birmingham, AL 35205, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $37,000 firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to Southern Research Institute. The contract is for COVID-19 compound testing and cytotoxicity screening in the SARS-CoV-2 CPE assay. This non-competitive award was made under simplified acquisition procedures, with the vendor selected due to prior work on the compound testing. The period of performance runs through...
This is a $37,000.00 firm fixed price purchase order contract awarded by the National Center for Advancing Translational Sciences, part of the U.S. Department of Health and Human Services, to Southern Research Institute, a non-profit research organization, for compound testing and cytotoxicity screening related to SARS-CoV-2. The contract does not have a set-aside designation. Through past federal contracts and grants, Southern Research has provided a range of research and development services...
This firm-fixed-price purchase order contract was awarded by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to the Southern Research Institute, a non-profit research organization. The $42,000 contract is for COVID-19 compound testing and cytotoxicity screening in the SARS-CoV-2 CPE assay. This work supports NCATS' mission of advancing the translation of medical discoveries into clinical applications. The contract has no...
This firm fixed-price purchase order was awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to Southern Research Institute to conduct COVID-19 compound testing and cytotoxicity screening in the SARS-CoV-2 cytopathic effect (CPE) assay across two rounds. The $74,000.00 contract has an ultimate completion date of August 28, 2020 and was not set aside for any specific business type. Southern Research Institute is a...
This federal contract award, valued at $79,000.00, was issued by the National Center for Advancing Translational Sciences (NCATS), a civilian agency, to the Southern Research Institute, a non-profit organization, for "HIGH-THROUGHPUT SARS-COV-2 ALPHALISA SCREENING FOR COVID-19 DRUG DISCOVERY - ANTIVIRAL INITIATIVE". The contract has a firm fixed price and was awarded on a non-competitive basis with no set-aside designation. Based on the agency and description, this contract supports...
This firm-fixed-price purchase order contract, valued at $47,000.00, was awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency, to Southern Research Institute, a non-profit organization, for COVID-19 compound dose response testing. The contract has no set-aside designation and is part of NCATS' efforts to evaluate potential COVID-19 treatments. Southern Research Institute has a history of providing drug discovery, development, and testing services to...
This is a firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to Southern Research Institute for $27,500.00. The contract is for assay development to measure the SARS-CoV-2 antiviral effect of remdesivir and the development of an AlphaLISA assay to be conducted under biosafety level 3 (BSL-3) conditions. This non-competitive contract was awarded without full and open competition due to...
This is a firm fixed-price purchase order awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, a civilian agency, to Southern Research Institute, a non-profit organization, for $7,500.00. The purpose is to conduct testing of MAP30-TAT x dexamethasone samples to evaluate their inhibition of COVID-19 binding to the ACE2 receptor in cell culture. This award is not associated with a set-aside program. Southern Research Institute has experience providing a range of...
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. Department of Health and Human Services, to Southern Research Institute, a corporate non-profit organization. The $452,600 contract is for the delivery of a "COMPREHENSIVE PANEL FOR VIRUSES" and is categorized as a Delivery Order under the NIAID's In Vitro Antimicrobial Assessments 2011-2018 contract vehicle. The contract has a firm fixed price and does not...
This is a $37,522 Firm Fixed Price delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Southern Research Institute, a corporate entity tax-exempt non-profit organization. The contract is to provide in vitro assessment for antimicrobial activity, and is part of the broader In Vitro Antimicrobial Assessments 2011-2018 IDIQ contract vehicle. Southern Research Institute has extensive experience providing research and development...